* Dynavax Technologies Corp DVAX.OQ DVAX.O is expected
to show
a fall in quarterly revenue when it reports results on February
23.
* The Emeryville California-based company is expected to
report
a 7.9% decrease in revenue to $179.603 million from $195.07
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Dynavax
Technologies Corp
is for earnings of 43 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Dynavax
Technologies Corp is $22, above its last closing price
of $10.73.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 0.34 0.33 0.43 Beat 31.3
Jun. 30 2022 0.22 0.22 0.87 Beat 295.5
Mar. 31 2022 0.24 0.24 0.22 Missed -8.3
Dec. 31 2021 0.61 0.64 0.55 Missed -14.1
Sep. 0.03 0.05 -0.24 Missed -625.5
30 2021
Jun. 30 2021 -0.05 -0.04 0.02 Beat 155.1
Mar. 31 2021 -0.01 -0.02 0.01 Beat 150
Dec. 31 2020 -0.24 -0.24 -0.14 Beat 42.5
This summary was machine generated February 22 at 03:01 GMT.
All figures in US dollars unless otherwise stated